Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dongguan Hec Cordyceps R&D Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is assigned to 1 distinct examiner, representing a focused point of prosecution. The data indicates that 1 distinct art unit is handling the matter, which suggests the technology is categorized within a specific biological or pharmaceutical niche. This concentration simplifies the administrative oversight but places the outcome of the 1 pending action in the hands of a single examiner.
MCINTOSH III, TRAVISS C is the busiest examiner for this portfolio, currently managing 1 pending office action. This single action constitutes the entire pending workload for the company at this time. Consequently, the immediate success of the portfolio's prosecution depends on the interaction with this 1 examiner within the designated art unit. With 1 pending action and 1 examiner, the company's current strategy is entirely focused on the feedback and requirements of MCINTOSH III, TRAVISS C within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCINTOSH III, TRAVISS C | 1 | 73.2% | +14.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279150 | GLUCOCEREBROSIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | MCINTOSH III, TRAVISS C | 37d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279150 | GLUCOCEREBROSIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | MCINTOSH III, TRAVISS C | 37d overdue |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18279150 | GLUCOCEREBROSIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | MCINTOSH III, TRAVISS C | 1693 | §101 | Final Rejection | 37d overdue | Pending | Aug 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial